Piper Sandler lowered the firm’s price target on BioMarin to $115 from $125 and keeps an Overweight rating on the shares after a momentous Q3 call. While the CEO transition is big news, the focus is on one of BioMarin’s uglier quarters in some time, the firm says. Revenue missed by $28M, driven by shortfalls across the portfolio.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMRN:
- BioMarin names Alexander Hardy CEO, succeeding Jean-Jacques Bienaime
- BioMarin narrows 2023 non-GAAP EPS $1.90-$2.05 from $1.85-$2.10, consensus $1.02
- BioMarin reports Q3 non-GAAP EPS 46c, consensus 22c
- BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
- Notable companies reporting after market close